|
Nov 9
|
Results: Lantheus Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
|
|
Nov 8
|
Lantheus Holdings Third Quarter 2024 Earnings: Beats Expectations
|
|
Nov 7
|
Lantheus Holdings Inc (LNTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Nov 7
|
Q3 2024 Lantheus Holdings Inc Earnings Call
|
|
Nov 6
|
Lantheus Holdings: Q3 Earnings Snapshot
|
|
Nov 6
|
Lantheus Reports Third Quarter 2024 Financial Results
|
|
Nov 4
|
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
|
|
Oct 8
|
Lantheus Holdings (NASDAQ:LNTH) Is Very Good At Capital Allocation
|
|
Sep 25
|
Medical Leader Lantheus Headed Toward Buy Point After Support At Key Level
|
|
Sep 25
|
Robust Quarterly Result Lifted Lantheus (LNTH) in Q2
|
|
Sep 22
|
Questor: A 300pc share price rise reflects the value of this cancer spotter
|
|
Sep 18
|
Lantheus Holdings (NASDAQ:LNTH) shareholder returns have been fantastic, earning 306% in 3 years
|
|
Sep 15
|
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
|
|
Aug 28
|
We Ran A Stock Scan For Earnings Growth And Lantheus Holdings (NASDAQ:LNTH) Passed With Ease
|
|
Aug 28
|
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 1
|
Lantheus Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Jul 31
|
Lantheus Holdings: Q2 Earnings Snapshot
|
|
Jul 31
|
Lantheus Reports Second Quarter 2024 Financial Results
|
|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|
|
Jun 27
|
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
|